ArticleNature communications2021
Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Formononetin as a potential therapeutic agent for asthma: evidence from in vivo and in vitro models of attenuated inflammation via cAMP/PKA pathway inhibition.In vitro cellular & developmental biology. Animal · 2026Article
- Current understanding and future directions in severe asthma through artificial intelligence-integrated multi-omic approaches.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Emerging Therapeutic Strategies in Asthma: Advances in Treatment, Drug Delivery, Drug Adherence, and Disease Management.Current allergy and asthma reports · 2026Review
- Neutrophil extracellular traps induce airway epithelial-mesenchymal transition in a neutrophil-dominant asthmatic murine model through Hedgehog/Gli1 pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- EV-associated non-coding RNAs in paediatric asthma airway remodelling: current mechanistic evidence and therapeutic perspectives.Frontiers in pharmacology · 2026Review
- Exploring the Efficacy and Mechanism of Astragalus Polysaccharide in Treating Allergic Asthma through Network Pharmacology, Bioinformatics, and Experimental Verification.Combinatorial chemistry & high throughput screening · 2026Article
- Dynamic Regulation of Collagens, Proteases, Their Inhibitors, and Cell Death in Experimental Asthma in Mice.Allergy · 2026Article
- Preparation of ESAT6-Fc Fusion Protein and Its Therapeutic Efficacy and Immune Mechanisms in Allergic Asthma Mice via Intranasal Immunization.Molecules (Basel, Switzerland) · 2025Article
- An Anti-IL-13 Vaccine Reduces Atopic Dermatitis in Humanized Mice and Induces Neutralizing Antibodies in Nonhuman Primates.Allergy · 2025Article
- Mechanisms of Innate Immune Modulation by High-Fat Diet: Implications for Obesity and Asthma.Current allergy and asthma reports · 2025Review
- Oral Administration of Trichosanthes Kirilowii Fruit Extract Ameliorates Airway Inflammation and Suppresses Th2 Cell Activities in Ovalbumin-Sensitized Mice.The Kaohsiung journal of medical sciences · 2025Article
- Association between geriatric nutritional risk index (GNRI) and asthma in elderly individuals aged 60 and above: a cross-sectional study of the NHANES 2005-2018.BMC pulmonary medicine · 2025Article
- Mediating role of basophils in the triacylglycerol-asthma link: a Mendelian randomization study.3 Biotech · 2025Article
- Mendelian randomization analysis reveals causal relationship between allergic diseases and influenza.The World Allergy Organization journal · 2025Article
- Clinical development of therapeutic mRNA applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Review
- Advances in diagnosis and treatment of lung cancer-associated obstructive pneumonia and lung abscess: synergistic strategies for infection control and antitumor therapy.Frontiers in cellular and infection microbiology · 2025Review
- The Circadian Rhythm of Asthma Immune Metabolism.Journal of immunology research · 2025Review
- Serum cytokine profiles in patients with myasthenia gravis.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic asthma is characterized by elevated levels of IgE antibodies, type 2 cytokines such as interleukin-4 (IL-4) and IL-13, airway hyperresponsiveness (AHR), mucus hypersecretion and eosinophilia. Approved therapeutic monoclonal antibodies targeting IgE or IL-4/IL-13 reduce asthma symptoms but require costly lifelong administrations. Here, we develop conjugate vaccines against mouse IL-4 and IL-13, and demonstrate their prophylactic and therapeutic efficacy in reducing IgE levels, AHR, eosinophilia and mucus production in mouse models of asthma analyzed up to 15 weeks after initial vaccination. More importantly, we also test similar vaccines specific for human IL-4/IL-13 in mice expressing human IL-4/IL-13 and the related receptor, IL-4Rα, to find efficient neutralization of both cytokines and reduced IgE levels for at least 11 weeks post-vaccination. Our results imply that dual IL-4/IL-13 vaccination may represent a cost-effective, long-term therapeutic strategy for the treatment of allergic asthma as demonstrated in mouse models, although additional studies are warranted to assess its safety and feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.